Autopsy report · NCT04064879

The Use of Autologous Mesenchymal Stem Cell Preparation for Treatment of Refractory Migraine

“Pending FDA approval”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year after it had already started.
• Suspended: paused, and may or may not restart.
• 10 participants enrolled.

Vital statistics

Status

Suspended

Phase

Na

Sponsor

Neurological Associates of West Los Angeles

Sponsor type

University, hospital or other

Conditions

Chronic Migraine, Headache

Interventions

AD-SVF

Participants

10

Sites

1

Countries

United States

Trials that died the same way

• Perceval S Aortic Heart Valve Study- North America
  “FDA approval” (90% match in meaning)
• Electrical Impedence Tomography With ENLIGHT2100
  “Device received FDA approval” (80% match in meaning)
• Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)
  “FDA reviewing” (76% match in meaning)
• Comparison Study of PET/CT or PET/MRI Imaging to Magnetic Resonance Imaging (MRI) Alone in Men With Prostate Cancer
  “Study Drug was FDA approved Summer 2021” (72% match in meaning)
• Safety of SP-420 in the Treatment of Transfusional Iron Overload
  “Study is on hold by FDA in the US.” (71% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.